Detalhe da pesquisa
1.
Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Lancet
; 403(10422): 160-170, 2024 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104575
2.
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia.
N Engl J Med
; 384(8): 717-726, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626254
3.
Clinical Trial of New Drug for Schizophrenia. Reply.
N Engl J Med
; 384(25): e105, 2021 06 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34161716
4.
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia.
Biol Psychiatry
; 2024 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38537670
5.
Efficacy and Safety of Xanomeline-Trospium Chloride in Schizophrenia: A Randomized Clinical Trial.
JAMA Psychiatry
; 2024 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38691387
6.
Evidence of trospium's ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results.
Psychopharmacology (Berl)
; 240(5): 1191-1198, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37036495
7.
Antipsychotic Efficacy of KarXT (Xanomeline-Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study.
J Clin Psychiatry
; 83(3)2022 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35552528
8.
Safety and tolerability of KarXT (xanomeline-trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia.
Schizophrenia (Heidelb)
; 8(1): 109, 2022 Dec 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463237
9.
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study.
Transl Psychiatry
; 12(1): 491, 2022 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-36414626
10.
Site-independent confirmation of primary site-based PANSS ratings in a schizophrenia trial.
J Psychiatr Res
; 144: 241-246, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34700212
11.
Effects of pioglitazone on mnemonic hippocampal function: A blood oxygen level-dependent functional magnetic resonance imaging study in elderly adults.
Alzheimers Dement (N Y)
; 5: 254-263, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31304231
12.
The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.
Alzheimers Dement (N Y)
; 5: 661-670, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31720367
13.
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine.
Int Clin Psychopharmacol
; 23(3): 161-9, 2008 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-18408530
14.
VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms.
Neuropsychopharmacology
; 31(7): 1345-55, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16641939
15.
A call for comparative effectiveness research to learn whether routine clinical care decisions can protect from dementia and cognitive decline.
Alzheimers Res Ther
; 8: 33, 2016 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-27543171
16.
Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial.
Biol Psychiatry
; 58(5): 347-54, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16139580
17.
Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study.
Biol Psychiatry
; 58(5): 355-63, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16139581
18.
A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression.
Biol Psychiatry
; 58(5): 364-73, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16139582
19.
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder.
J Clin Psychiatry
; 66(6): 686-92, 2005 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-15960560
20.
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
J Psychiatr Res
; 39(2): 161-72, 2005 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15589564